Development and Validation of a Quantitative LC-MS/MS Method for Measuring CYP4V2 Enzyme Activity via 12-Hydroxylauric Acid in rAAV-hCYP4V2 Gene Therapy Products
Open Access
Abstract
Bietti crystalline dystrophy (BCD) is a hereditary retinal disease caused by loss-of-function mutations in the CYP4V2 gene. Gene replacement therapy using rAAV-hCYP4V2 represents a promising therapeutic strategy, requiring robust bioassays for product quality control. This study developed and validated a sensitive LC-MS/MS method for quantifying CYP4V2 enzyme activity. Lysates from HeLa-AAVR cells transduced with rAAV-hCYP4V2 (MOI = 3 × 105) were used, with lauric acid as substrate supplemented with cytochrome P450 reductase, cytochrome b5, and NADPH. The ω-hydroxylated product (12-hydroxy lauric acid) was quantified using tolbutamide as an internal standard. Method validation followed ICH guidelines. Results demonstrated excellent specificity with negligible background in negative controls. Linearity was achieved over 0.5–100 ng/mL (R2 > 0.99), with an average recovery of 100.6%. Intra-batch and inter-batch precision RSDs were <47.8% and <28.4%, respectively. Product stability was maintained for ≥4 weeks at −80°C. The method was successfully applied to three AAV serotypes (AAV2, AAV8, and AAV2/8), with all RSDs < 23.9%. This validated LC-MS/MS bioassay provides a crucial quality control tool for potency assessment, process development, batch release, and stability studies of rAAV-hCYP4V2 gene therapy products.Keywords
All Related Versions
Funding Information
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z251100004625002)
- the National Key R&D Program of China (2023YFC3403305)
This publication has 27 references indexed in Scilit:
- Comprehensive genotypic and phenotypic analysis of Bietti crystalline dystrophy: insights from a large cohort studyScience China Life Sciences, 2025
- Preclinical studies of an AAV8-CYP4V2 gene therapy VGR-R01 for the treatment of Bietti crystalline dystrophyMolecular Therapy - Methods & Clinical Development, 2025
- Safety and Vision Outcomes Following Gene Therapy for Bietti Crystalline DystrophyJAMA Ophthalmology, 2025
- Targeted lipidomics uncovers oxylipin perturbations and potential circulation biomarkers in Bietti’s crystalline dystrophyGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and reviewBiochemical Pharmacology, 2024
- CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD)Biochemical Pharmacology, 2022
- Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductaseBiochemical and Biophysical Research Communications, 2019
- Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4Drug Metabolism and Pharmacokinetics, 2019
- Human cytochrome P450 expression in bacteria: Whole-cell high-throughput activity assay for CYP1A2, 2A6 and 3A4Biochemical Pharmacology, 2018
- Cytochrome P450 4A11 inhibition assays based on characterization of lauric acid metabolitesFood and Chemical Toxicology, 2018